MK 677

Description

Buy MK 677 by Dragon Pharma – Premium Ibutamoren 25 mg

DragonPharma.Net offers pharmaceutical-grade MK 677 by Dragon Pharma, lab-tested and trusted by athletes and bodybuilders worldwide. Each bottle contains 100 tablets dosed at 25 mg. Fast shipping available from USA (2–5 days) and international warehouses (7–21 days).

What is MK 677 (Ibutamoren)?

MK 677, also known as Ibutamoren, is a non-peptide growth hormone secretagogue that stimulates the natural release of growth hormone (GH) and IGF-1. Unlike GH injections, it mimics ghrelin to increase hormone levels without altering testosterone or estrogen.

This compound is commonly used for lean mass gains, improved recovery, better sleep, and fat loss. While not a SARM, MK 677 is often stacked alongside SARMs like LGD 4033 or Ostarine due to its synergistic effects.

Benefits of MK 677

• Stimulates natural GH and IGF-1 release
• Promotes lean muscle growth and recovery
• Improves sleep quality and cognitive function
• Supports fat loss and metabolism
• Enhances skin, hair, and joint health

Recommended Dosage & Cycle

Typical dosage is 25 mg/day for 8–12 weeks. Beginners can start at 10–15 mg to assess tolerance. Due to its long half-life (~24 hours), once-daily dosing is sufficient. MK 677 is often run longer than traditional SARMs to see full benefits.

Adverse Effects & Safety

MK 677 is generally well-tolerated. Some users report increased appetite, mild water retention, or fatigue during the initial weeks. These effects often subside with consistent use. Always monitor blood glucose and avoid stacking with insulin-sensitizing agents without medical guidance.

Does MK 677 Require PCT?

No traditional post-cycle therapy (PCT) is needed since MK 677 is non-suppressive. However, breaks between cycles may help maintain sensitivity to its effects. Users stacking it with SARMs or steroids should consider PCT based on the entire cycle.

Example MK 677 Cycle

• Weeks 1–12: MK 677 – 25 mg/day
• Optional Stack: LGD 4033 or Andarine

MK 677 Lab Test Report